Page last updated: 2024-10-30

lorazepam and Audiogenic Epilepsy

lorazepam has been researched along with Audiogenic Epilepsy in 3 studies

Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.

Research Excerpts

Excerpt	Relevance	Reference
"Photosensitive epilepsy is a type of reflex epilepsy."	1.31	Lorazepam: an adjuvant therapy in patients with seizure and heliotaxis. ( Madhusudanan, M; Oomman, A, 2001)

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Gurrell, R	1
Gorman, D	1
Whitlock, M	1
Ogden, A	1
Reynolds, DS	1
DiVentura, B	1
Abou-Khalil, B	1
Gelfand, M	1
Pollard, J	1
Hogan, RE	1
Krauss, G	1
Sperling, M	1
Vazquez, B	1
Wechsler, RT	1
Friedman, D	1
Butt, RP	1
French, J	1
Nath, C	1
Gupta, MB	1
Oomman, A	1
Madhusudanan, M	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
A Double Blind, Randomized, Cross- Over Study Examining Efficacy Of Pf-06372865 In A Photosensitivity Epilepsy Study Using Lorazepam As A Positive Control[NCT02564029]			Phase 2	7 participants (Actual)	Interventional	2015-12-16	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-06372865

(NCT02564029)
Timeframe: Pre-dose, 1, 2, 3, 4 and 6 hours post-dose

Intervention	ng*hr/mL (Geometric Mean)
PF-06372865 17.5 mg	331.3
PF-06372865 52.5 mg	771.4

Maximum Plasma Concentration (Cmax) of PF-06372865

(NCT02564029)
Timeframe: 1, 2, 4 and 6 hours post-dose

Intervention	ng/mL (Geometric Mean)
PF-06372865 17.5 mg	81.30
PF-06372865 52.5 mg	200.6

Number of Participants With Clinically Significant Change From Baseline in Blood Pressure and Pulse Rate

(NCT02564029)
Timeframe: 17 weeks

Intervention	Participants (Number)
PF-06372865 17.5 mg	0
PF-06372865 52.5 mg	0
Lorazepam 2 mg	0
Placebo	0

Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings

(NCT02564029)
Timeframe: 17 weeks

Intervention	Participants (Number)
PF-06372865 17.5 mg	0
PF-06372865 52.5 mg	0
Lorazepam 2 mg	0
Placebo	0

Number of Participants With Clinically Significant Laboratory Test Abnormalities

Safety laboratory tests included hematological, clinical chemistry (serum) and urinalysis safety tests. (NCT02564029)
Timeframe: 17 weeks

Intervention	Participants (Number)
PF-06372865 17.5 mg	0
PF-06372865 52.5 mg	0
Lorazepam 2 mg	0
Placebo	0

The Standardized Photosensitivity Range (SPR) in the Subject's Most Sensitive Eye Condition

The SPR was defined as the number of frequency steps between and including the lower and upper bound at which a generalized electroencephalogram (EEG) epileptiform activity had occurred, whereby subjects were exposed to 14 different frequencies ranging from 2 to 60 flashes per second. The SPR is then an integer score that ranges from 0 to 14 with lower scores representing better outcomes. The primary outcome measure was based on the average Least Squares Mean (LSmean) effect over the first 6 hours postdose. (NCT02564029)
Timeframe: Pre-dose, 1, 2, 4 and 6 hours post-dose

Intervention	Units on a scale (Least Squares Mean)
PF-06372865 17.5 mg	0.57
PF-06372865 52.5 mg	1.38
Lorazepam 2 mg	1.58
Placebo	6.80

Time for Cmax (Tmax) of PF-06372865

(NCT02564029)
Timeframe: 1, 2, 4 and 6 hours post-dose

Intervention	hour (Median)
PF-06372865 17.5 mg	2.12
PF-06372865 52.5 mg	3.02

Number of Participants With Treatment-emergent Adverse Events (AEs)

The all causalities treatment-emergent AEs by System Organ Class and Preferred Term in >5% of subjects. AEs included serious AEs and non-serious AEs. (NCT02564029)
Timeframe: 19 weeks

,,,

Intervention	Participants (Number)
	Treatment-emergent non serious AEs	Treatment-emergent serious AEs
Lorazepam 2 mg	6	0
PF-06372865 17.5 mg	4	0
PF-06372865 52.5 mg	6	0
Placebo	5	0

Plasma Concentration of Lorazepam

(NCT02564029)
Timeframe: 1, 2, 3, 4 and 6 hours post-dose

Intervention	ng/mL (Mean)
	1 hours post dose	2 hours post dose	3 hours post dose	4 hours post dose	6 hours post dose
Lorazepam 2 mg	7.38	13.32	17.10	17.87	15.93

The Percentage of Participants With Complete Suppression, Partial Response, and no Response to Intermittent Photic Stimulation (IPS)

Complete suppression: SPR = 0 in all three eye conditions at the same time point. Partial response: A reduction in SPR of at least 3 units from baseline for at least 3 time points, and no time points with at least 3 units of increase, in the most sensitive eye condition; without meeting the complete suppression definition. No response: Did not meet complete suppression or partial response definitions. (NCT02564029)
Timeframe: Pre-dose, 1, 2, 4 and 6 hours post-dose

,,,

Intervention	Percentage of participants (Number)
	Complete suppression	Partial response	No response
Lorazepam 2 mg	85.7	0	14.3
PF-06372865 17.5 mg	85.7	0	14.3
PF-06372865 52.5 mg	85.7	0	14.3
Placebo	28.6	0	71.4

The SPR in the Eye Closure, Eyes Closed, and Eyes Open Condition

The SPR was defined as the number of frequency steps between and including the lower and upper bound at which a generalized electroencephalogram (EEG) epileptiform activity had occurred, whereby subjects were exposed to 14 different frequencies ranging from 2 to 60 flashes per second. The SPR is then an integer score that ranges from 0 to 14 with lower scores representing better outcomes. The outcome measure was based on the average Least Squares Mean (LSmean) effect over the first 6 hours postdose. (NCT02564029)
Timeframe: Pre-dose, 1, 2, 4 and 6 hours post-dose

,,,

Intervention	Units on a scale (Least Squares Mean)
	Eye Closure	Eyes Closed	Eyes Open
Lorazepam 2 mg	1.58	1.09	0.08
PF-06372865 17.5 mg	0.57	0.33	0.04
PF-06372865 52.5 mg	1.38	0.40	0.09
Placebo	6.80	6.84	4.46

Trials

1 trial available for lorazepam and Audiogenic Epilepsy

Article	Year
Photosensitive epilepsy: Robust clinical efficacy of a selective GABA potentiator. Neurology, 2019, 04-09, Volume: 92, Issue:15 Topics: Adolescent; Adult; Anticonvulsants; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Bli	2019

Other Studies

2 other studies available for lorazepam and Audiogenic Epilepsy

Article	Year
Role of central histaminergic system in lorazepam withdrawal syndrome in rats. Pharmacology, biochemistry, and behavior, 2001, Volume: 68, Issue:4 Topics: Acoustic Stimulation; Animals; Anti-Anxiety Agents; Epilepsy, Reflex; Histamine; Histamine Agonists;	2001
Lorazepam: an adjuvant therapy in patients with seizure and heliotaxis. Neurology India, 2001, Volume: 49, Issue:3 Topics: Adolescent; Anticonvulsants; Child; Epilepsy, Reflex; Female; Humans; Lorazepam; Male; Middle Aged;	2001